![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Southwest Hospital, China Chongqing Science&Technology Commission |
---|---|
Information provided by: | Southwest Hospital, China |
ClinicalTrials.gov Identifier: | NCT00730860 |
A prospective randomized study was conducted to elucidate whether the outcome of hepatocellular carcinoma could be improved by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization.
Condition | Intervention |
---|---|
Cancer of Liver |
Procedure: radiofrequency ablation associated with TACE Procedure: radiofrequency ablation only |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation Associated With Postoperative Transhepatic Arterial Chemoembolization——a Prospective Randomized Clinical Trial |
Estimated Enrollment: | 140 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
|
Procedure: radiofrequency ablation associated with TACE
treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
|
2: Active Comparator
treatment of hepatocellular carcinoma by radiofrequency ablation only
|
Procedure: radiofrequency ablation only
treatment of hepatocellular carcinoma by radiofrequency ablation only
|
A prospective randomized study was conducted to elucidate whether the outcome of hepatocellular carcinoma could be improved by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Feng Xiaobin, M.D | +86-23-68765297 | fengxiaobin200708@yahoo.com.cn |
China | |
Institute of hepatobiliary surgery | Recruiting |
Chongqing, China, 400038 | |
Contact: Ma Kuansheng, Ph.D 86-23-68765297 xiaobinf@medmail.com.cn | |
Principal Investigator: Feng Xiaobin, M.D |
Study Director: | Ma Kuansheng, Ph.D | Institute of Hepatobiliary surgery , Southwest hospital |
Responsible Party: | Southwest Hospital ( feng xiaobin ) |
Study ID Numbers: | SWHB002 |
Study First Received: | August 6, 2008 |
Last Updated: | December 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00730860 |
Health Authority: | China: Ethics Committee |
radiofrequency ablation Cancer of Liver postoperative transhepatic arterial chemoembolization prospective |
Liver Neoplasms Liver Diseases Digestive System Diseases Digestive System Neoplasms Carcinoma, Hepatocellular Liver neoplasms |
Gastrointestinal Neoplasms Adenocarcinoma Hepatocellular carcinoma Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type |